Key clinical point: Quality of life was the most frequently cited reason for starting second-line therapy in children with immune thrombocytopenia.
Major finding: Quality of life was chosen as a reason to treat in 73% of patients, it was among the top three reasons in 57% of patients, and it was the most important reason in 27%.
Study details: A survey of hematologists treating 120 children in an observational study.
Disclosures: The speaker reported involvement in an investigator-initiated trial for eltrombopag in children with ITP. The study, which has not yet opened, is funded by Novartis.
Shimano KA et al. ASPHO 2019, Abstract 2012.
Must Reads in Hematology
Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research
SaO2 vs PaO2 in Cyanotic Patients Evaluated, JAMA Pediatr; ePub Aug 21; Ahmed, et al